|
About Sidney Kahn
In addition to his quotidian pharmacovigilance responsibilities, Dr. Kahn has been an active participant in US and international pharmacovigilance groups, including:
Dr. Kahn is currently a member of the CIOMS VI working group on clinical trial safety assessment and the DIA GCDM Terminology Management SIAC. In his most recent industry position as Executive Director, Global Pharmacovigilance and Labeling, Bristol-Myers Squibb Company, he managed a large group of physicians and scientists responsible for the safety assessment of investigational and marketed products and personally developed innovative approaches to signal detection and evaluation and risk management plans for developmental and newly marketed products. Dr. Kahn has given many presentations on various aspects of pharmacovigilance, including:
| |||||||
|
Pharmacovigilance & Risk Management, Inc. pvrm@comcast.net
|
||||||||
|
Copyright © 2002 Pharmacovigilance & Risk Management,
Inc. |
Dr.
Sidney Kahn has been at the forefront of recent US and international
developments in pharmacovigilance, risk assessment, and risk management
for the past decade. He holds a medical degree from the University
of Cape Town, South Africa, a Ph.D. from the University of London,
and specialist certification in Chemical Pathology (Clinical Biochemistry)
by the Royal College of Pathologists, London. He is also a member
of the Faculty of Pharmaceutical Medicine of the Royal College
of Physicians, U.K. After 17 years in academic laboratory medicine
in the UK and USA directing large hospital laboratories and conducting
basic research in clinical biochemistry and neuroimmunology, he joined the pharmaceutical industry in 1990
and began working on safety assessment of medicinal products throughout
their life cycle.